Olmesartan Glenmark Pharmaceuticals Europe (Olmesartan Medoxomil)

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

• Hypertension: helps lower systolic and diastolic blood pressure in adults.
• Heart failure: used as part of combination therapy to improve cardiac output and reduce hospitalisation risk.
• Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes.

• Olmesartan medoxil selectively blocks the binding of angiotensin II to the AT1 receptors on vascular smooth‑muscle and adrenal cells. This inhibition prevents vasoconstriction and aldosterone release, leading to reduced peripheral resistance, lower blood pressure and decreased sodium‑water retention.

Olmesartan medoxil may cause adverse reactions that vary in frequency and severity.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Nasal congestion
• Diarrhoea
• Upper respiratory tract infection

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Liver enzyme elevations
• Allergic skin reactions such as Stevens‑Johnson syndrome

When prescribing Olmesartan medoxil, clinicians should consider several safety aspects.

• Renal function monitoring: assess baseline creatinine and eGFR, especially in patients with chronic kidney disease.
• Electrolyte balance: check serum potassium periodically, as hyperkalaemia may occur.
• Pregnancy: avoid use during the second and third trimesters due to fetal toxicity.
• Concomitant NSAID therapy: may reduce antihy‑pertensive effect and increase renal risk.
• Elderly patients: start with a lower dose and monitor for orthostatic hypotension.
• Store at below 25°C: keep in the original packaging , protect from moisture.

Olmesartan medoxil can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., lisinopril, aliskiren) – heightened risk of hypotension, hyperkalaemia and renal impairment.
• Potassium‑rich supplements or potassium‑sparing diuretics – may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflamatory    ---
• NSAIDs: may blunt antihypertensive response and affect renal function.
• Diuretics (thiazide or loop): may enhance hypotensive effect; monitor blood pressure.
• Lithium: increased lithium levels and risk of toxicity.
• CYP  ---        ---